Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450085 | 0.84 | ALDH1A1 (0.38) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2452707 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2447651 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2449251 | 0.82 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2449762 | 0.82 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2451574 | 0.81 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2449489 | 0.81 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2451576 | 0.81 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2449746 | 0.81 | CYP19A1 (0.36) | ADRB2ADRB1ADRB3TBXA2RCNR1 | |
| SCHEMBL2452051 | 0.81 | LIPG (0.38) | LIPGADRB2ADRB1ADRB3PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | LIPG 4573/4885ADRB2 16/4885ADRB1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.